Vomizole 40mg powder for injection
Ingredients in every vial
Each package contains
|ATC Level 1||A - Alimentary tract and metabolism|
|ATC Level 2||A02 - Drugs for Acid Related Disorders|
|ATC Level 3||A02B - Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)|
0 TO 18 YEARS OLD
Safety and efficacy in children have not been established.
18 TO 65 YEARS OLD
The intravenous administration is recommended
only if oral application is not appropriate.
Duodenal ulcer, gastric ulcer, reflux esophagitis:
The recommended intravenous dosage is one vial (40 mg pantoprazole) per day.
Zollinger-Ellison syndrome & other pathological hypersecretory conditions:
Patients should start their treatment with a daily dose of 80 mg pantoprazole IV. Thereafter, the dosage can be titrated up or down as needed using measurements of gastric acid secretion to guide. With doses above 80 mg daily, the dose should be divided and given twice daily. A temporary increase of the dosage above 160 mg pantoprazole is possible but should not be applied longer than required for adequate acid control. Transition from oral to IV and from IV to oral formulations of gastric acid inhibitors should be performed in such manner to ensure continuity of effect of suppression of acid secretion.
65 YEARS OLD AND ABOVE
The daily dose of 40 mg pantoprazole should not be exceeded in elderly patients
PATIENTS WITH IMPAIRED RENAL FUNCTION
The daily dose of 40 mg pantoprazole should not be exceeded in patients with impaired renal function.
PATIENTS WITH SEVERE LIVER IMPAIRMENT
In patients with severe liver impairment the daily dose has to be reduced to 20 mg pantoprazole. Furthermore, in these patients the liver enzymes should be monitored during pantoprazole IV therapy. In case of a rise of the liver enzymes pantoprazole IV should be discontinued.
– Duodenal ulcer
– Gastric ulcer
– Moderate and severe cases of inflammation of the esophagus (reflux esophagitis)
– Zollinger Ellison syndrome